(MENAFN- GlobeNewsWire - Nasdaq)
HAMILTON, Ontario, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“ Reliq ” or the“ Company ”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, wishes to inform shareholders that it will be hosting a webinar on Thursday, March 2nd, 2023 at 7:30am PST / 10:30am EST to review the Company's condensed interim consolidated financial statements for Q2 Fiscal Year 2023 (October 1 – December 31, 2022), and provide a corporate update.
Webinar Login Information:
| Date: || Thursday, March 2, 2023 |
| Time: || 7:30am PST / 10:30am EST |
| URL: || |
For those who are not able to attend the webinar, a recording will be available on the Company's website ( ) shortly after the webinar concludes.
Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN:A2AJTB.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.